Besides the clinical benefits of crizotinib in ALK-rearranged metastatic non-small cell lung cancer (NSCLC), concerns about its hepatotoxicity have arisen. It is not clear whether this is a drug class side effector if the use of other selective ALKs inhibitors is safe after this serious adverse event. |